Literature DB >> 6774045

Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis.

P W Berman, J Patrick.   

Abstract

Mice immunized with acetylcholine receptor (AChR) purified from Torpedo californica form anti-AChR antibodies and often develop muscular weakness and flaccid paralysis closely resembling the human disease myasthenia gravis. This condition, termed experimental myasthenia gravis (EMG), is strain dependent in that the frequency of paralysis is much greater in some strains than in others. Differences in the frequency of EMG might result from differences in the immune system or the neuromuscular junction. In these studies, we have identified two loci, the major histocompatibility complex (H-2) region on chromosome 17 and the region that contains the structural genes for the constant region of immunoglobulin heavy chains (IgCH region) on chromosome 12, which significantly effect the probability with which a mouse immunized with T. californica AChR can be expected to become paralyzed. One genotype (H-2b, Ig-1b) correlated with high susceptibility to EMG in four strains with three dissimilar backgrounds. These studies demonstrate that susceptibility to EMG is a heritable trait determined by at least two distinct loci that are linked to regions of the mouse genome that regulate immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6774045      PMCID: PMC2185932          DOI: 10.1084/jem.152.3.507

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Strain differences in the autoimmune response of mice to acetylcholine receptors.

Authors:  S Fuchs; D Nevo; R Tarrab-Hazdai; I Yaar
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

2.  Acetylcholine receptor antibodies in myasthenia gravis.

Authors:  S H Appel; R R Almon; N Levy
Journal:  N Engl J Med       Date:  1975-10-09       Impact factor: 91.245

Review 3.  Myasthenia gravis (second of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

4.  Autoimmune response to acetylcholine receptor.

Authors:  J Patrick; J Lindstrom
Journal:  Science       Date:  1973-05-25       Impact factor: 47.728

Review 5.  Acetylcholine receptor and myasthenia gravis.

Authors:  B W Fulpius; A D Zurn; D A Granato; R M Leder
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

6.  On the genetic dissection of a specific humoral immune response to alpha(1,3) dextran.

Authors:  W Geckeler; B Blomberg; C de Preval; M Cohn
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1977

7.  The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization.

Authors:  D C Shreffler; C S David
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

Review 8.  The immune response genes of the major histocompatibility complex.

Authors:  B Benacerraf; R N Germain
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

9.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

10.  Genetics of the antibody response to dextran in mice.

Authors:  B Blomberg; W R Geckeler; M Weigert
Journal:  Science       Date:  1972-07-14       Impact factor: 47.728

View more
  21 in total

1.  Ek alpha transgene in B10 mice suppresses the development of myasthenia gravis.

Authors:  P Christadoss; C S David; M Shenoy; S Keve
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Antigenic Liposomes for Generation of Disease-specific Antibodies.

Authors:  Kyle J Bednar; Lakeya Hardy; Johanna Smeekens; Dharmendra Raghuwanshi; Shiteng Duan; Mike D Kulis; Matthew S Macauley
Journal:  J Vis Exp       Date:  2018-10-25       Impact factor: 1.355

5.  Idiotypic determinants of natural IgM antibodies that resemble self Ia antigens.

Authors:  D Holmberg; S Forsgren; L Forni; F Ivars; A Coutinho
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

6.  In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor.

Authors:  M K Waldor; S Sriram; H O McDevitt; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

7.  Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.

Authors:  A Bionda; M H De Baets; S J Tzartos; J M Lindstrom; W O Weigle; A N Theophilopoulos
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

8.  Genetic analysis of the non-H-2-linked Ir genes controlling the cytotoxic T-cell response to H-Y in H-2d mice.

Authors:  W Fierz; G A Farmer; J H Sheena; E Simpson
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

9.  Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.

Authors:  Huan Yang; Yong Zhang; Minghua Wu; Jing Li; Wenbin Zhou; Guiyuan Li; Xiaoling Li; Bo Xiao; Premkumar Christadoss
Journal:  Inflamm Res       Date:  2009-09-19       Impact factor: 4.575

10.  Susceptibility to murine experimental autoallergic myasthenia gravis: the role of antibody specificity.

Authors:  A L Marzo; M J Garlepp; M Schon-Hegrad; R L Dawkins
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.